NAFDAC has burst massive buildings filled with expired drugs and supplements at Umumeje village, in Umuocheala community of ...

Just because you can buy a medication over the counter doesn’t mean it’s always safe. Here’s how you should really be using ...

Do not take DAPA-TABS if you have: severe liver disease or if you suffer from ... such as anuria or progressive and severe oliguria. low potassium levels in your blood. Do not take DAPA-TABS ...

Low-Level Traffic Air Pollution Linked to Liver Damage and Fatty Liver Disease Jan. 31, 2025 — Low levels of traffic-related air pollution harms the liver and may raise the risk of metabolic ...

The inflammation and scarring caused by excess fat may eventually lead to cirrhosis, which increases the risk of liver failure and liver cancer. This double whammy of fatty deposits may be a ...

"Low performers" are in the firing line. Meta began laying people off Monday after saying it would target its lowest performers. Microsoft also sent termination letters last month, telling people ...

Some or all of the mortgage lenders featured on our site are advertising partners of NerdWallet, but this does not influence our evaluations, lender star ratings or the order in which lenders are ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

Banas, Jr., MD; Murray Epstein, MD A final consideration in this issue is that age may independently influence the degree to which hypokalemia develops in an elderly diuretic-treated population ...

Pineapple contains nutrients and beneficial compounds, such as vitamin C, manganese, and enzymes. Eating pineapple may help boost immunity, lower cancer risk, and improve recovery time after ...

Most common in patients with poor kidney function, heart failure or liver disease treated with renin angiotensin aldosterone system (RAAS) inhibitors, hyperkalaemia can be fatal, and patients have ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...